TY  - JOUR
AU  - Bajić, Vladan. P.
AU  - Essack, Magbubah
AU  - Živković, Lada
AU  - Stewart, Alan
AU  - Zafirović, Sonja
AU  - Bajić, Vladimir B.
AU  - Gojobori, Takashi
AU  - Isenović, Esma
AU  - Spremo-Potparević, Biljana
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3554
AB  - Alzheimer’s disease (AD) is a neurodegenerative disease that affects millions of individuals worldwide and can occur relatively early or later in life. It is well known that genetic components, such as the amyloid precursor protein gene on chromosome 21, are fundamental in early-onset AD (EOAD). To date, however, only the apolipoprotein E4 (ApoE4) gene has been proved to be a genetic risk factor for late-onset AD (LOAD). In recent years, despite the hypothesis that many additional unidentified genes are likely to play a role in AD development, it is surprising that additional gene polymorphisms associated with LOAD have failed to come to light. In this review, we examine the role of X chromosome epigenetics and, based upon GWAS studies, the PCDHX11 gene. Furthermore, we explore other genetic risk factors of AD that involve X-chromosome epigenetics.
PB  - Frontiers Media S.A.
T2  - Frontiers in Genetics
T1  - The X Files: “The Mystery of X Chromosome Instability in Alzheimer’s Disease”
VL  - 10
DO  - 10.3389/fgene.2019.01368
ER  - 

@article{
author = "Bajić, Vladan. P. and Essack, Magbubah and Živković, Lada and Stewart, Alan and Zafirović, Sonja and Bajić, Vladimir B. and Gojobori, Takashi and Isenović, Esma and Spremo-Potparević, Biljana",
year = "2020",
abstract = "Alzheimer’s disease (AD) is a neurodegenerative disease that affects millions of individuals worldwide and can occur relatively early or later in life. It is well known that genetic components, such as the amyloid precursor protein gene on chromosome 21, are fundamental in early-onset AD (EOAD). To date, however, only the apolipoprotein E4 (ApoE4) gene has been proved to be a genetic risk factor for late-onset AD (LOAD). In recent years, despite the hypothesis that many additional unidentified genes are likely to play a role in AD development, it is surprising that additional gene polymorphisms associated with LOAD have failed to come to light. In this review, we examine the role of X chromosome epigenetics and, based upon GWAS studies, the PCDHX11 gene. Furthermore, we explore other genetic risk factors of AD that involve X-chromosome epigenetics.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Genetics",
title = "The X Files: “The Mystery of X Chromosome Instability in Alzheimer’s Disease”",
volume = "10",
doi = "10.3389/fgene.2019.01368"
}

Bajić, Vladan. P., Essack, M., Živković, L., Stewart, A., Zafirović, S., Bajić, V. B., Gojobori, T., Isenović, E.,& Spremo-Potparević, B.. (2020). The X Files: “The Mystery of X Chromosome Instability in Alzheimer’s Disease”. in Frontiers in Genetics
Frontiers Media S.A.., 10.
https://doi.org/10.3389/fgene.2019.01368

Bajić VP, Essack M, Živković L, Stewart A, Zafirović S, Bajić VB, Gojobori T, Isenović E, Spremo-Potparević B. The X Files: “The Mystery of X Chromosome Instability in Alzheimer’s Disease”. in Frontiers in Genetics. 2020;10.
doi:10.3389/fgene.2019.01368 .

Bajić, Vladan. P., Essack, Magbubah, Živković, Lada, Stewart, Alan, Zafirović, Sonja, Bajić, Vladimir B., Gojobori, Takashi, Isenović, Esma, Spremo-Potparević, Biljana, "The X Files: “The Mystery of X Chromosome Instability in Alzheimer’s Disease”" in Frontiers in Genetics, 10 (2020),
https://doi.org/10.3389/fgene.2019.01368 . .

TY  - JOUR
AU  - Obradović, Milan
AU  - Zafirović, Sonja
AU  - Essack, Magbubah
AU  - Dimitrov, Jelena
AU  - Živković, Lada
AU  - Spremo-Potparević, Biljana
AU  - Radak, Đorđe
AU  - Bajić, Vladimir B.
AU  - Isenović, Esma
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3462
AB  - To remedy carotid artery stenosis and prevent stroke surgical intervention is commonly used, and the gold standard being carotid endarterectomy (CEA). During CEA cerebrovascular hemoglobin oxygen saturation decreases and when this decrease reaches critical levels it leads to cerebral hypoxia that causes neuronal damage. One of the proposed mechanism that affects changes during CEA and contribute to acute brain ischemia (ABI) is oxidative stress. The increased production of reactive oxygen species and reactive nitrogen species during ABI may cause an unregulated inflammatory response and further lead to structural and functional injury of neurons. Antioxidant activity are involved in the protection against neuronal damage after cerebral ischemia. We hypothesized that neuronal injury and poor outcomes in patients undergoing CEA may be results of oxidative stress that disturbed function of antioxidant enzymes and contributed to the DNA damage in lymphocytes.
PB  - Elsevier
T2  - Medical Hypotheses
T1  - Antioxidant enzymes expression in lymphocytes of patients undergoing carotid endarterectomy
VL  - 134
SP  - 1
EP  - 5
DO  - 10.1016/j.mehy.2019.109419
ER  - 

@article{
author = "Obradović, Milan and Zafirović, Sonja and Essack, Magbubah and Dimitrov, Jelena and Živković, Lada and Spremo-Potparević, Biljana and Radak, Đorđe and Bajić, Vladimir B. and Isenović, Esma",
year = "2020",
abstract = "To remedy carotid artery stenosis and prevent stroke surgical intervention is commonly used, and the gold standard being carotid endarterectomy (CEA). During CEA cerebrovascular hemoglobin oxygen saturation decreases and when this decrease reaches critical levels it leads to cerebral hypoxia that causes neuronal damage. One of the proposed mechanism that affects changes during CEA and contribute to acute brain ischemia (ABI) is oxidative stress. The increased production of reactive oxygen species and reactive nitrogen species during ABI may cause an unregulated inflammatory response and further lead to structural and functional injury of neurons. Antioxidant activity are involved in the protection against neuronal damage after cerebral ischemia. We hypothesized that neuronal injury and poor outcomes in patients undergoing CEA may be results of oxidative stress that disturbed function of antioxidant enzymes and contributed to the DNA damage in lymphocytes.",
publisher = "Elsevier",
journal = "Medical Hypotheses",
title = "Antioxidant enzymes expression in lymphocytes of patients undergoing carotid endarterectomy",
volume = "134",
pages = "1-5",
doi = "10.1016/j.mehy.2019.109419"
}

Obradović, M., Zafirović, S., Essack, M., Dimitrov, J., Živković, L., Spremo-Potparević, B., Radak, Đ., Bajić, V. B.,& Isenović, E.. (2020). Antioxidant enzymes expression in lymphocytes of patients undergoing carotid endarterectomy. in Medical Hypotheses
Elsevier., 134, 1-5.
https://doi.org/10.1016/j.mehy.2019.109419

Obradović M, Zafirović S, Essack M, Dimitrov J, Živković L, Spremo-Potparević B, Radak Đ, Bajić VB, Isenović E. Antioxidant enzymes expression in lymphocytes of patients undergoing carotid endarterectomy. in Medical Hypotheses. 2020;134:1-5.
doi:10.1016/j.mehy.2019.109419 .

Obradović, Milan, Zafirović, Sonja, Essack, Magbubah, Dimitrov, Jelena, Živković, Lada, Spremo-Potparević, Biljana, Radak, Đorđe, Bajić, Vladimir B., Isenović, Esma, "Antioxidant enzymes expression in lymphocytes of patients undergoing carotid endarterectomy" in Medical Hypotheses, 134 (2020):1-5,
https://doi.org/10.1016/j.mehy.2019.109419 . .

TY  - JOUR
AU  - Bajić, Vladan
AU  - Sudar-Milovanović, Emina
AU  - Potparević, Biljana
AU  - Živković, Lada
AU  - Miliccivc, Zorka
AU  - Stanimirović, Julijana
AU  - Bogdanović, Nikola
AU  - Isenović, Esma
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2591
AB  - Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Pharmaceutical Analysis
T1  - Treatment of Alzheimer's Disease: Classical Therapeutic Approach
VL  - 12
IS  - 2
SP  - 82
EP  - 90
DO  - 10.2174/1573412911666150611184740
ER  - 

@article{
author = "Bajić, Vladan and Sudar-Milovanović, Emina and Potparević, Biljana and Živković, Lada and Miliccivc, Zorka and Stanimirović, Julijana and Bogdanović, Nikola and Isenović, Esma",
year = "2016",
abstract = "Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Pharmaceutical Analysis",
title = "Treatment of Alzheimer's Disease: Classical Therapeutic Approach",
volume = "12",
number = "2",
pages = "82-90",
doi = "10.2174/1573412911666150611184740"
}

Bajić, V., Sudar-Milovanović, E., Potparević, B., Živković, L., Miliccivc, Z., Stanimirović, J., Bogdanović, N.,& Isenović, E.. (2016). Treatment of Alzheimer's Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis
Bentham Science Publ Ltd, Sharjah., 12(2), 82-90.
https://doi.org/10.2174/1573412911666150611184740

Bajić V, Sudar-Milovanović E, Potparević B, Živković L, Miliccivc Z, Stanimirović J, Bogdanović N, Isenović E. Treatment of Alzheimer's Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis. 2016;12(2):82-90.
doi:10.2174/1573412911666150611184740 .

Bajić, Vladan, Sudar-Milovanović, Emina, Potparević, Biljana, Živković, Lada, Miliccivc, Zorka, Stanimirović, Julijana, Bogdanović, Nikola, Isenović, Esma, "Treatment of Alzheimer's Disease: Classical Therapeutic Approach" in Current Pharmaceutical Analysis, 12, no. 2 (2016):82-90,
https://doi.org/10.2174/1573412911666150611184740 . .

TY  - JOUR
AU  - Unić-Stojanović, Dragana
AU  - Isenović, Esma
AU  - Jović, Miomir
AU  - Maravić-Stojković, Vera
AU  - Miljković, Milica
AU  - Gojković, Tamara
AU  - Milicić, Biljana
AU  - Bogdanović, Nikola
AU  - Radak, Đorđe
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2758
AB  - Copeptin is a sensitive and more stable surrogate marker for arginine vasopressin. In this study, we evaluated copeptin levels in carotid endarterectomy (CEA) patients, perioperatively, to determine whether copeptin levels can be related to carotid artery cross clamping (CC) time and to postoperative neurological outcomes. Copeptin, interleukin 6, C-reactive protein, cortisol, and brain natriuretic peptide were measured preoperatively (T1) and 3 hours postoperatively (T3) as well as intraoperatively (T2). We recruited 77 patients. Values of copeptin rose gradually over the observed times: T1 = 7.9 (6.4-9.6), T2 = 12.6 (9.3-16.8), and T3 = 72.3 (49.1-111.2) pmol/L. There was a significant difference for repeated measurement (P = .000, P = .000, and P = .000). Duration of carotid artery CC during CEA does not affect postoperative copeptin level (CC 13 minutes: 106.8 +/- 93.6 pmol/L, CC > 13 minutes: 96.7 +/- 89.1 pmol/L; P = .634). Preoperative copeptin level was significantly higher in patients with ulcerated plaque morphology. Activation of the stress axis in patients undergoing CEA results in copeptin elevation. Duration of CC during CEA does not affect postoperative copeptin levels.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Angiology
T1  - Copeptin Levels Do Not Correlate With Cross-Clamping Time in Patients Undergoing Carotid Endarterectomy Under General Anesthesia
VL  - 67
IS  - 10
SP  - 951
EP  - 960
DO  - 10.1177/0003319716629322
ER  - 

@article{
author = "Unić-Stojanović, Dragana and Isenović, Esma and Jović, Miomir and Maravić-Stojković, Vera and Miljković, Milica and Gojković, Tamara and Milicić, Biljana and Bogdanović, Nikola and Radak, Đorđe",
year = "2016",
abstract = "Copeptin is a sensitive and more stable surrogate marker for arginine vasopressin. In this study, we evaluated copeptin levels in carotid endarterectomy (CEA) patients, perioperatively, to determine whether copeptin levels can be related to carotid artery cross clamping (CC) time and to postoperative neurological outcomes. Copeptin, interleukin 6, C-reactive protein, cortisol, and brain natriuretic peptide were measured preoperatively (T1) and 3 hours postoperatively (T3) as well as intraoperatively (T2). We recruited 77 patients. Values of copeptin rose gradually over the observed times: T1 = 7.9 (6.4-9.6), T2 = 12.6 (9.3-16.8), and T3 = 72.3 (49.1-111.2) pmol/L. There was a significant difference for repeated measurement (P = .000, P = .000, and P = .000). Duration of carotid artery CC during CEA does not affect postoperative copeptin level (CC 13 minutes: 106.8 +/- 93.6 pmol/L, CC > 13 minutes: 96.7 +/- 89.1 pmol/L; P = .634). Preoperative copeptin level was significantly higher in patients with ulcerated plaque morphology. Activation of the stress axis in patients undergoing CEA results in copeptin elevation. Duration of CC during CEA does not affect postoperative copeptin levels.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Angiology",
title = "Copeptin Levels Do Not Correlate With Cross-Clamping Time in Patients Undergoing Carotid Endarterectomy Under General Anesthesia",
volume = "67",
number = "10",
pages = "951-960",
doi = "10.1177/0003319716629322"
}

Unić-Stojanović, D., Isenović, E., Jović, M., Maravić-Stojković, V., Miljković, M., Gojković, T., Milicić, B., Bogdanović, N.,& Radak, Đ.. (2016). Copeptin Levels Do Not Correlate With Cross-Clamping Time in Patients Undergoing Carotid Endarterectomy Under General Anesthesia. in Angiology
Sage Publications Inc, Thousand Oaks., 67(10), 951-960.
https://doi.org/10.1177/0003319716629322

Unić-Stojanović D, Isenović E, Jović M, Maravić-Stojković V, Miljković M, Gojković T, Milicić B, Bogdanović N, Radak Đ. Copeptin Levels Do Not Correlate With Cross-Clamping Time in Patients Undergoing Carotid Endarterectomy Under General Anesthesia. in Angiology. 2016;67(10):951-960.
doi:10.1177/0003319716629322 .

Unić-Stojanović, Dragana, Isenović, Esma, Jović, Miomir, Maravić-Stojković, Vera, Miljković, Milica, Gojković, Tamara, Milicić, Biljana, Bogdanović, Nikola, Radak, Đorđe, "Copeptin Levels Do Not Correlate With Cross-Clamping Time in Patients Undergoing Carotid Endarterectomy Under General Anesthesia" in Angiology, 67, no. 10 (2016):951-960,
https://doi.org/10.1177/0003319716629322 . .

TY  - JOUR
AU  - Bajić, Vladan
AU  - Potparević, Biljana
AU  - Živković, Lada
AU  - Sudar, Emina
AU  - Zafirović, Sonja
AU  - Obradović, Milan
AU  - Isenović, Esma
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2446
AB  - Alzheimer's disease (AD) is a multi factorial disease, related to the loss of neurons and synapses in cerebral cortex and subcortical structures, leading to degenerative changes and atrophy. Despite abundance of facts related to AD and its pathology, the only drugs used in the prevention and treatment are those from the cholinesterase inhibitors group. However, there is growing evidence that a non-classical therapeutic approach in the treatment of AD has beneficial effects. In this review we summarized recent literature data related to the non-classical drugs for the treatment of AD predominantly used in clinical testing, such as amyloid aggregation inhibitors, beta-sheet breakers, antioxidants, estrogens and immunotherapeutics.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Letters in Drug Design and Discovery
T1  - Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
VL  - 12
IS  - 2
SP  - 158
EP  - 164
UR  - https://hdl.handle.net/21.15107/rcub_vinar_398
ER  - 

@article{
author = "Bajić, Vladan and Potparević, Biljana and Živković, Lada and Sudar, Emina and Zafirović, Sonja and Obradović, Milan and Isenović, Esma",
year = "2015",
abstract = "Alzheimer's disease (AD) is a multi factorial disease, related to the loss of neurons and synapses in cerebral cortex and subcortical structures, leading to degenerative changes and atrophy. Despite abundance of facts related to AD and its pathology, the only drugs used in the prevention and treatment are those from the cholinesterase inhibitors group. However, there is growing evidence that a non-classical therapeutic approach in the treatment of AD has beneficial effects. In this review we summarized recent literature data related to the non-classical drugs for the treatment of AD predominantly used in clinical testing, such as amyloid aggregation inhibitors, beta-sheet breakers, antioxidants, estrogens and immunotherapeutics.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Letters in Drug Design and Discovery",
title = "Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review",
volume = "12",
number = "2",
pages = "158-164",
url = "https://hdl.handle.net/21.15107/rcub_vinar_398"
}

Bajić, V., Potparević, B., Živković, L., Sudar, E., Zafirović, S., Obradović, M.,& Isenović, E.. (2015). Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review. in Letters in Drug Design and Discovery
Bentham Science Publ Ltd, Sharjah., 12(2), 158-164.
https://hdl.handle.net/21.15107/rcub_vinar_398

Bajić V, Potparević B, Živković L, Sudar E, Zafirović S, Obradović M, Isenović E. Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review. in Letters in Drug Design and Discovery. 2015;12(2):158-164.
https://hdl.handle.net/21.15107/rcub_vinar_398 .

Bajić, Vladan, Potparević, Biljana, Živković, Lada, Sudar, Emina, Zafirović, Sonja, Obradović, Milan, Isenović, Esma, "Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review" in Letters in Drug Design and Discovery, 12, no. 2 (2015):158-164,
https://hdl.handle.net/21.15107/rcub_vinar_398 .